Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.

NCT00366171 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00366171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00366171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
October 31, 2007
Enrollment
120
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia